269 related articles for article (PubMed ID: 36648946)
21. Immunological Responses Associated With Neoadjuvant Therapy in the Tumor Microenvironment of Esophageal Squamous Cell Carcinoma.
Takehara Y; Tamaki T; Mimura K; Saito K; Neupane P; Tada T; Watanabe Y; Hayase S; Saze Z; Yoshimoto Y; Sato H; Kono K; Suzuki Y
Anticancer Res; 2023 Oct; 43(10):4691-4700. PubMed ID: 37772585
[TBL] [Abstract][Full Text] [Related]
22. Alleviation of neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma and its relationship with expression and changes of PD-L1.
Zhou YH; Li JY; Yan JX; Guo P; He WW; Liu Y
Neoplasma; 2022 Jul; 69(4):785-793. PubMed ID: 35400168
[TBL] [Abstract][Full Text] [Related]
23. Real-world management and outcomes of older patients with locally advanced esophageal squamous cell carcinoma: a multicenter retrospective study.
Saito Y; Hamamoto Y; Hirata K; Yamasaki M; Watanabe M; Abe T; Tsubosa Y; Hamai Y; Murakami K; Bamba T; Yoshii T; Tsuda M; Watanabe M; Ueno M; Kitagawa Y
BMC Cancer; 2023 Mar; 23(1):283. PubMed ID: 36978040
[TBL] [Abstract][Full Text] [Related]
24. PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus.
Fassan M; Cavallin F; Guzzardo V; Kotsafti A; Scarpa M; Cagol M; Chiarion-Sileni V; Maria Saadeh L; Alfieri R; Castagliuolo I; Rugge M; Castoro C; Scarpa M
Cancer Med; 2019 Oct; 8(13):6036-6048. PubMed ID: 31429521
[TBL] [Abstract][Full Text] [Related]
25. Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma.
Mitani S; Kawakami H; Shiraishi O; Kanemura H; Suzuki S; Haratani K; Hayashi H; Yonesaka K; Chiba Y; Yasuda T; Nakagawa K
Esophagus; 2023 Apr; 20(2):281-289. PubMed ID: 36484900
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8
Fukuoka E; Yamashita K; Tanaka T; Sawada R; Sugita Y; Arimoto A; Fujita M; Takiguchi G; Matsuda T; Oshikiri T; Nakamura T; Suzuki S; Kakeji Y
Anticancer Res; 2019 Aug; 39(8):4539-4548. PubMed ID: 31366557
[TBL] [Abstract][Full Text] [Related]
27. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
[TBL] [Abstract][Full Text] [Related]
28. Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma.
Kim R; Keam B; Kwon D; Ock CY; Kim M; Kim TM; Kim HJ; Jeon YK; Park IK; Kang CH; Kim DW; Kim YT; Heo DS
World J Gastroenterol; 2016 Oct; 22(37):8389-8397. PubMed ID: 27729745
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of PD-L1 and Siglec-15 expression in patients with nasopharyngeal carcinoma.
Zhao J; Yang H; Hu H; Liu C; Wei M; Zhao Y; Chen Y; Cui Y; Chen P; Xiong K; Lu Y; Yang H; Yang L
Sci Rep; 2022 Jun; 12(1):10401. PubMed ID: 35729260
[TBL] [Abstract][Full Text] [Related]
30. Treatment-Related Lymphopenia Predicts Pathologic Complete Response and Recurrence in Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy.
Li Q; Zhou S; Liu S; Liu S; Yang H; Zhao L; Liu M; Hu Y; Xi M
Ann Surg Oncol; 2019 Sep; 26(9):2882-2889. PubMed ID: 31037433
[TBL] [Abstract][Full Text] [Related]
31. Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy.
Huang WT; Lu HI; Wang YM; Chen YH; Lo CM; Lin WC; Lan YC; Tseng LH; Li SH
J Clin Med; 2019 Nov; 8(11):. PubMed ID: 31684197
[TBL] [Abstract][Full Text] [Related]
32. Immune cell patterns before and after neoadjuvant immune checkpoint blockade combined with chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
Zheng DD; Li YY; Yuan XY; Lu JL; Zhang MF; Fu J; Zhang CZ
BMC Cancer; 2024 May; 24(1):649. PubMed ID: 38802821
[TBL] [Abstract][Full Text] [Related]
33. Significance of TIM-3 Expression in Resected Esophageal Squamous Cell Carcinoma.
Zhao Y; Chen D; Wang W; Zhao T; Wen J; Zhang F; Duan S; Chen C; Sang Y; Zhang Y; Chen Y
Ann Thorac Surg; 2020 May; 109(5):1551-1557. PubMed ID: 31987829
[TBL] [Abstract][Full Text] [Related]
34. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
[TBL] [Abstract][Full Text] [Related]
35. From pixels to patient care: deep learning-enabled pathomics signature offers precise outcome predictions for immunotherapy in esophageal squamous cell cancer.
Li B; Qin W; Yang L; Li H; Jiang C; Yao Y; Cheng S; Zou B; Fan B; Dong T; Wang L
J Transl Med; 2024 Feb; 22(1):195. PubMed ID: 38388379
[TBL] [Abstract][Full Text] [Related]
36. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
Gong L; Mao W; Chen Q; Jiang Y; Fan Y
Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
[TBL] [Abstract][Full Text] [Related]
37. Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer.
Shafi S; Aung TN; Xirou V; Gavrielatou N; Vathiotis IA; Fernandez A; Moutafi M; Yaghoobi V; Herbst RS; Liu LN; Langermann S; Rimm DL
Lab Invest; 2022 Oct; 102(10):1143-1149. PubMed ID: 35581307
[TBL] [Abstract][Full Text] [Related]
38. Comparison of long-term outcomes between esophagectomy and chemoradiotherapy after endoscopic resection of submucosal esophageal squamous cell carcinoma.
Tanaka T; Ueno M; Iizuka T; Hoteya S; Haruta S; Udagawa H
Dis Esophagus; 2019 Dec; 32(12):. PubMed ID: 30980070
[TBL] [Abstract][Full Text] [Related]
39. CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer.
Zhu Y; Li M; Mu D; Kong L; Zhang J; Zhao F; Li Z; Liu X; Bo C; Yu J
Oncotarget; 2016 Nov; 7(44):71455-71465. PubMed ID: 27683115
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]